http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Boston Scientific (BSX) Agrees to Acquire Symetis SA for $435M
-
Boston Scientific Announces Agreement to Acquire Symetis
-
NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife™ Battery Technology For Treatment Of Heart Failure
-
Edwards Lifesciences (EW) Announces German Court Ruled Boston Scientific's (BSX) Lotus Valve Infringes One Patents but Does Not Infringe Second
-
Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation
-
Boston Scientific To Participate In Barclays Global Healthcare Conference
-
Boston Scientific Announces Six Finalists in 2nd Annual Connected Patient Challenge, Focused on Healthcare Data Analytics
-
Edwards Lifesciences (EW) Says UK Patent Court's Initial Decision on Boston Scientific's (BSX) Patents Finds One Invalid, Second Infringed
-
Boston Scientific to Participate in Cowen and Company 37th Annual Healthcare Conference
-
Boston Scientific to Participate in 2017 RBC Capital Markets Global Healthcare Conference
-
Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
-
Boston Scientific To Participate In LEERINK Partners 6th Annual Global Healthcare Conference
-
Boston Scientific To Webcast Conference Call Discussing Fourth Quarter 2016 Financial Results And Announces 2017 Investor Day Business Review
-
Boston Scientific To Participate In 35th Annual J.P. Morgan Healthcare Conference
-
Boston Scientific (BSX) Closes Acquisition of Neovasc (NVCN) Advanced Biological Tissue Capabilities, Acquires 15% Stake
-
Boston Scientific Closes Acquisition of Advanced Biological Tissue Capabilities and Acquires Common Shares of Neovasc, Inc.
-
Notable Mergers and Acquisitions 12/2: (VASC)/(TFX) (TWTR) (III) (BSX)/(NVCN)
-
Boston Scientific (BSX) Accquires Certain Assets, 15% Equity Stake in of Neovasc (NVCN) for $75M
-
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
-
Boston Scientific To Participate In Citi 2016 Global Healthcare Conference
-
Boston Scientific (BSX) Announces C Losing of $210 EndoChoice (GI) Acquisition
-
Boston Scientific Closes EndoChoice Acquisition
-
Boston Scientific Receives 2016 Shingo Prize for Operational Excellence
-
Boston Scientific To Participate In Piper Jaffray 2016 Healthcare Conference
-
Boston Scientific (BSX) Announces Positive Data from First HeartLogic Trial in Predicting HF Decompression
-
Boston Scientific Announces Positive Results Of HeartLogic™ Heart Failure Diagnostic Service
-
Boston Scientific (BSX) Acquires Distal Access' Gynecology and Urology Portfolio
-
Boston Scientific Acquires Resectr™ Tissue Resection Device from Distal Access, LLC
-
Boston Scientific (BSX) Extends EndoChoice Tender Offer
-
Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice
-
Boston Scientific (BSX) Acquires LumenR's LumenR Tissue Retractor System
-
Boston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System
-
Boston Scientific (BSX) Announces Initial U.S. Commercial Data on WATCHMAN LAAC; High Rate of Success Noted
-
Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device
-
Primary Endpoint from Study of Drug Eluting Coronary Stent in Underserved Patient Populations Presented at TCT 2016
-
Boston Scientific To Participate In Stifel 2016 Healthcare Conference
-
Boston Scientific Announces Results For Third Quarter 2016
-
Boston Scientific To Participate In 25th Annual Credit Suisse Healthcare Conference
-
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2016
-
Boston Scientific Launches Resolution 360™ Clip
-
Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
-
Boston Scientific (BSX) Begins $8/Share Tender for EndoChoice (GI)
-
Boston Scientific Commences Cash Tender Offer For All Shares Of EndoChoice For $8.00 Per Share In Cash
-
Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 Financial Results on October 26
-
Boston Scientific (BSX) to Acquire EndoChoice (GI) in ~$210M Deal
-
Boston Scientific to Acquire EndoChoice
-
Boston Scientific's (BSX) LOTUS Edge Valve System Receives CE Mark
-
Boston Scientific Receives CE Mark For LOTUS Edge™ Valve System
-
Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference
-
Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference

